Glenmark Pharmaceuticals Inc., USA announced on May 18, 2026, the launch of Vancomycin Hydrochloride for Injection USP in two strengths — 500 mg/vial and 1 g/vial — from its base in Elmwood Park, New Jersey. The product is bioequivalent and therapeutically equivalent to the reference listed drug, Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial, of Fresenius Kabi USA, LLC. This launch further expands the company's injectable portfolio in the United States market.

Product and Market Overview

The newly launched product enters a market that has demonstrated notable commercial scale. According to IQVIA® National Sales Perspectives: Retail & Non-Retail data for the 12-month period ending March 2026, the Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial market achieved annual sales of approximately $37.9 million. The market figure includes the brand and all available therapeutic equivalents.

Key details of the product launch are summarised below:

Leadership Commentary

Commenting on the launch, Marc Kikuchi, President & Business Head, North America, said, "The launch of Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial reflects Glenmark's continued commitment to expanding access to quality, affordable medicines in the U.S. It also strengthens our injectable portfolio and reinforces our focus on delivering reliable treatment options to healthcare providers and patients."

About Glenmark Pharmaceuticals Limited

Glenmark Pharmaceuticals Ltd. is a global, research-led pharmaceutical company with a focus on innovation and accessibility. The company operates 11 manufacturing facilities across four continents, supported by six R&D centres, and maintains a commercial presence in 80+ countries. Its diversified portfolio spans branded, innovative, generics, and consumer health products, with a focus on respiratory, dermatology, and oncology. Scrip 100 positions Glenmark among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024.

Note: Glenmark's Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial is approved only for the indication(s) listed in Glenmark's approved label. IQVIA® data obtained by Glenmark is only available for all approved RLD indications; Glenmark's product is only approved for the indications listed in its approved label and is not marketed for all RLD indications.

Glenmark Pharmaceuticals has received final approval from the U.S. Food and Drug Administration (FDA) for its Progesterone Vaginal Inserts, 100 mg, marking a significant regulatory milestone for the pharmaceutical company. The FDA determined the product to be bioequivalent and therapeutically equivalent to the reference listed drug Endometrin® Vaginal Inserts, 100 mg of Ferring Pharmaceuticals Inc.

Regulatory Achievement and Market Entry

The FDA approval represents a major achievement in Glenmark's U.S. market expansion strategy. The company's progesterone vaginal inserts will be distributed in the United States by Glenmark Pharmaceuticals Inc., USA, providing direct access to this therapeutic market segment.

Market Opportunity and Commercial Potential

According to IQVIA® sales data for the 12-month period ending February 2026, the Endometrin® Vaginal Inserts, 100 mg market achieved annual sales of approximately $59.20 million. This substantial market size underscores the commercial significance of Glenmark's regulatory success in the women's healthcare segment.

Strategic Impact on Women's Healthcare Portfolio

Marc Kikuchi, President & Business Head, North America, emphasized the company's commitment to expanding access to quality and affordable medicines. "This approval for Progesterone Vaginal Inserts, 100 mg marks an important addition to our business and reinforces our focus on addressing patient needs in women's healthcare," Kikuchi stated.

The approval strengthens Glenmark's position in the competitive U.S. pharmaceutical market, particularly enhancing its women's healthcare product portfolio. This regulatory milestone demonstrates the company's capability to successfully navigate the stringent FDA approval process while maintaining focus on therapeutic equivalence and quality standards.